Cigna Drug and Biologic Coverage Policy

Similar documents
Capital BlueCross Open/Closed Formulary Update (1 st Quarter 2017)

Cigna Drug and Biologic Coverage Policy

Generic Label Name Drug Strength Dosage Form Example Product (s) MME/Unit ACETAMINOPHEN WITH CODEINE

Opioid Management Program May 2018

Opioid Management Program October 2018

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Pequot Health Care Opioid Analgesic Quantity Program*

Pharmacy Medical Necessity Guidelines: Opioid Analgesics

Opioid Analgesic/Opioid Combination Products

APPROVED PA CRITERIA. Initial Approval: January 10, 2018 Revised Dates: April 11, 2018 CRITERIA FOR PRIOR AUTHORIZATION

New Hampshire Healthy Families CLINICAL POLICY

Opioid Analgesic/Opioid Combination Products

Opiate/Benzodiazepine/Muscle Relaxant Combinations

Xyrem (Sodium Oxybate)

Prior Authorization Opioid Overutilization 2017

: Opioid Quantity Limits

MEDICARE Program Policies & Procedures POLICY NUMBER: Medicare D-111

PRESCRIPTION DRUG LIST CHANGES

20/0.8mg, 30/1.2mg, Films 90 MME/day Belbuca (buprenorphine) 75mcg, 150mcg, 300mcg, 450mcg 60 units per 90 days

Texas Prior Authorization Program Clinical Edit Criteria

Carefirst. +.V Family of health care plans

Long-Acting Opioid Analgesics

Long-Acting Opioid Analgesics

CHANGES TO YOUR DRUG LIST

AETNA BETTER HEALTH Prior Authorization guideline for Narcotic Analgesic Utilization

Prior Authorization for Opioid Products Indicated for Pain Management

Prior Authorization Guideline

PRESCRIPTION DRUG PROGRAM FORMULARY UPDATES Select Formulary October 1, 2018 Updates. Formulary. Alternatives

ADDITIONAL 2017 FORMULARY CHANGES CIGNA COMMERCIAL CUSTOMERS

Opioids, Extended Release (ER) Quantity Limit Criteria Program Summary

ADDITIONAL 2017 FORMULARY CHANGES CIGNA COMMERCIAL CUSTOMERS

Medication Policy Manual. Topic: Immediate-release (IR) Opioid Medication Products for Pain. Date of Origin: January 1, 2018

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Beneficiary Advisory Panel Handout Uniform Formulary Decisions 24 June 2010

Morphine Sulfate Hydromorphone Oxymorphone

See Important Reminder at the end of this policy for important regulatory and legal information.

Disposal of Unused Medicines: What You Should Know

Disposal of Unused Medicines: What You Should Know

Nucynta IR/ Nucynta ER (tapentadol immediate-release and extendedrelease)

15 mg morphine 10 mg hydrocodone

Embeda. Embeda (morphine sulfate and naltrexone hydrochloride) Description

Limitations of use: Subsys may be dispensed only to patients enrolled in the TIRF REMS Access program (1).

Opioid Analgesics. Recommended starting dose for opioid-naïve patients

Committee Approval Date: September 12, 2014 Next Review Date: September 2015

1/29/2013. Schedule II Controlled Substances: Basics and Beyond. Controlled Substances. Controlled Substances, Schedule I

``Considerations for using opioid drug therapy in workers compensation include patient safety, drug effectiveness and financial impacts

Demerol (meperidine oral tablet, oral solution), Meperitab (oral tablet)

Long-Acting Opioid. Policy Number: Last Review: 12/2017 Origination: 09/2013 Next Review: 09/2018

How To Green My Pharmacy. Prepared and presented by Luna El Bizri,Pharm-D, Community Pharmacist

Opioid Analgesic Treatment Worksheet

QUANTITY LIMIT AND POST LIMIT PRIOR AUTHORIZATION CRITERIA

Cigna Drug and Biologic Coverage Policy

Opioid Capture in the AHSQC Can we reduce use by measuring it? Michael Reinhorn MD, MBA, FACS Dept of Surgery, Newton Wellesley Hospital

Clinical Policy: Opioid Analgesics Reference Number: OH.PHAR.PPA.13 Effective Date: 10/2017 Last Review Date: 6/2018 Line of Business: Medicaid

Proposed Changes to Existing Measure for HEDIS : Use of Opioids at High Dosage (UOD)

Equianalgesic Dosing of Opioids for Pain Management

Drug Use Evaluation: Short Acting Opioids (SAO)

Future Formulary Changes

Disposal by Flushing of Certain Unused Medicines: What

STEP THERAPY WITH QUANTITY LIMIT AND POST LIMIT PRIOR AUTHORIZATION CRITERIA. AVINZA (morphine extended-release capsules)

Drug Name (specify drug) Quantity Frequency Strength

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

Session II. Learning Objectives for Session II. Key Principles of Safe Prescribing. Benefits and Limitations of ER/LA Opioids

See Important Reminder at the end of this policy for important regulatory and legal information.

Pharmacy Management Drug Policy

See Important Reminder at the end of this policy for important regulatory and legal information.

Oxymorphone (Opana ) is indicated for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate.

Methadone. Description

Duragesic patch. Duragesic patch (fentanyl patch) Description

EXTENDED RELEASE OPIOID DRUGS

See Important Reminder at the end of this policy for important regulatory and legal information.

Opioid Analgesic Treatment Worksheet

Slide 1. Slide 2. Slide 3. Opioid (Narcotic) Analgesics and Antagonists. Lesson 6.1. Lesson 6.1. Opioid (Narcotic) Analgesics and Antagonists

Drug Name (specify drug) Quantity Frequency Strength

Demystifying Opioid Conversion Calculations

10 mg hydrocodone equals how much oxycodone

PAIN. TREATMENT TABLES Analgesics. NON-OPIOID ANALGESICS Generic Name Trade Names (Examples) Duration Initial Dose

** Fee-For-Service Pharmacy Provider Notice #229 May 2018 PDL Changes **

See Important Reminder at the end of this policy for important regulatory and legal information.

Transmucosal Immediate Release Fentanyl (TIRF) Prior Authorization, (Through Generic), and Quantity Limit Program Summary

Addressing Drug Diversion

NATL. II. Health Net Approved Indications and Usage Guidelines: Diagnosis of cancer AND. Member is on fentanyl transdermal patches AND

Medication Policy Manual. Topic: Extended-release (ER) Opioid Medication Products for Pain. Date of Origin: January 1, 2018

Medication Policy Manual. Date of Origin: January 1, Topic: Extended-release (ER) Opioid Medication Products for Pain

Conversion chart from fentanyl to opana er

Bree Collaborative AMDG Opioid Prescribing Guidelines Workgroup. Opioid Prescribing Metrics - DRAFT

Drug Formulary Commission

2019 LIST OF COVERED DRUGS (FORMULARY)

Texas Vendor Drug Program. Drug Use Criteria: Hydrocodone Bitartrate/ Hydrocodone Polistirex. Publication History

Opioid Prescribing Guidelines for Patients in the Emergency Department

Let s Talk About. Pain Medicines. wisconsin. health literacy. A division of Wisconsin Literacy, Inc.

Hydrocodone 10mg vs oxycodone 10 mg. What is the difference between oxycontin and oxycodone hcl 1 acetaminophen with oxycodone and roxicodone 5mg

Immediate Release Opioid Analgesics (Brand and Generic): Acute Pain Duration Limit with MME Limit and Post Limit Policy

Extended Release Opioid Drugs

Percocet 10 without acetaminophen

USE OF OPIODS AT HIGHER DOSES IN PERSONS WITHOUT CANCER: MORPHINE EQUIVALENT DOSE EDIT

Transcription:

Cigna Drug and Biologic Coverage Policy Subject Controlled Substance Analgesic and Narcotic Antagonist Quantity Limitations Table of Contents Coverage Policy... 1 General Background... 6 Coding/Billing Information... 10 References... 10 Effective Date 1/1/2018 Next Review Date...5/15/2018 Coverage Policy Number..1706 Related Coverage Resources Transmucosal Fentanyl - (1018) Opioid Therapy - (1704) INSTRUCTIONS FOR USE The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer s benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer s benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations. Coverage Policy Cigna covers drugs in excess of the Quantity Limit requirements, in accordance with benefit plan specifications, as medically necessary when the following criteria have been met: Dosage, frequency, site of administration, and duration of therapy is not contraindicated or otherwise not recommended in the FDA product information (Label). Dosage, frequency, site of administration, and duration of therapy should be reasonable, clinically appropriate, and supported by evidence-based literature and adjusted based upon severity, alternative available treatments, and previous response to therapy as applicable For opioid therapy only, attestation that opioids will be prescribed in accordance with current clinical practice guidelines AND that an assessment of risks, harms, and goals consistent with an opioid agreement (or similar agreement) has been undertaken. Specific s: LONG-ACTING OPIOIDS FENTANYL Page 1 of 10

LONG-ACTING OPIOIDS Fentanyl (Duragesic) Patch HYDROCODONE Hydrocodone (Hysingla ER)Tablet Hydrocodone (Zohydro ER)Capsule 15 patches per 30 days 1 tablet per day 10 mg, 15 mg, 20 mg, 30 mg, 40 mg: 2 capsules per day 50 mg: 4 capsules per day HYDROMORPHONE Hydromorphone (Exalgo) Tablet 8mg: 1 tablet per day 12mg, 32mg: 2 tablets per day 16 mg: 4 tablets per day MORPHINE SULFATE Morphine sulfate (Arymo ER) Tablet 3 tablets per day Morphine sulfate (Avinza) Capsule 3 capsules per day Morphine sulfate (Kadian) Capsule 3 capsules per day Morphine sulfate (Morphabond ER) Tablet 2 tablets per day Morphine sulfate (MS Contin) Tablet 4 tablets per day MORPHINE-NALTREXONE Morphine-Naltrexone (Embeda) Capsule 3 capsules per day OXYCODONE Oxycodone (Oxycontin)Tablet 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 60 mg: 2 tablets per day 80 mg: 4 tablets per day Oxycodone (Xtampza ER) Capsule 9mg, 13.5mg,18mg: 2 capsules per day 27mg: 4 capsules per day 36mg: 8 capsules per day OXYMORPHONE Oxymorphone (Opana ER) Tablet 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 30 mg: 2 tablets per day 40 mg: 4 tablets per day SHORT-ACTING OPIOIDS CODEINE SULFATE Codeine Sulfate Liquid 960 ml per 30 days Codeine SulfateTablet CODEINE-ACETAMINOPHEN Codeine-Acetaminophen Liquid 960 ml per 30 days Codeine-Acetaminophen Tablet CODEINE-CARISOPRODOL-ASPIRIN Codeine-Carisoprodol-Aspirin Tablet DIHYDROCODEINE COMBINATIONS Dihydrocodeine-Caffeine-Acetaminophen (Trezix) Capsule 180 capsules per 30 days Dihydrocodeine-Caffeine-Acetaminophen Tablet Dihydrocodeine-Caffeine-Aspirin (Synalgos-DC) Capsule 180 capsules per 30 days FENTANYL Fentanyl (Abstral) Sublingual Tablet 100mcg: 128 tablets per 30 days 200mcg, 300mcg, 400mcg, 600mcg, 800mcg: 96 tablets per 30 days Fentanyl (Actiq) Lozenge 90 lozenges per 30 days Page 2 of 10

SHORT-ACTING OPIOIDS Fentanyl (Fentora) Buccal Tablet 100mcg: 112 tablets per 30 days 200mcg, 400mcg, 600mcg, 800mcg: 84 tablets per 30 days Fentanyl (Lazanda) Nasal Spray 100mcg: 15 bottles (120 sprays) per 30 days 300mcg, 400mcg: 10 bottles (80 sprays) per 30 days Fentanyl (Onsolis) Film 90 films per 30 days Fentanyl (Subsys) Sublingual Spray 100mcg: 120 sprays per 30 days 200mcg, 400mcg, 600mcg, 800mcg, 1200mcg, 1600mcg: 90 sprays per 30 days HYDROCODONE-ACETAMINOPHEN Hydrocodone-Acetaminophen (Lortab,Zamicet) Liquid 960 ml per 30 days 2.5-108mg, 2.5-167mg, 5-163mg, 5-217mg, 5-334mg, 7.5-325mg, 7.5-500mg, 10-300mg, 10-325mg Hydrocodone-Acetaminophen (Lorcet HD) Capsule 180 capsules per 30 days Hydrocodone-Acetaminophen (Norco, Vicodin ES, Vicodin HP, Xodol) Tablet 2.5-500mg, 5-400mg, 5-500mg, 7.5-300mg, 7.5-325mg, 7.5-400mg, 7.5-500mg, 7.5-650mg, 7.5-750mg, 10-300mg, 10-325,10-400mg, 10-500mg, 10-650mg, 10-660mg, 10-750mg Hydrocodone-Acetaminophen (Norco, Verdocet, Xodol) 270 tablets per 30 days 2.5-325mg, 5-300mg, 5-325mg HYDROCODONE-IBUPROFEN Hydrocodone-Ibuprofen (Reprexain, Vicoprofen, Xylon) Tablet Maximum daily dose 5 tablets 2.5-200mg, 5-200mg, 7.5-200mg, 10-200mg HYDROMORPHONE Hydromorphone Liquid 480 ml per 30 days Hydromorphone Suppository 120 suppositories per 30 days Hydromorphone Tablet 2mg, 4mg: 8mg: 90 tablets per 30 days LEVORPHANOL Levorphanol 120 tablets per 30 days MEPERIDINE Meperidine Liquid 960 ml per 30 days Meperidine Tablet METHADONE Methadone Liquid 1800 ml per 30 days Methadose Oral Concentrate 360 ml per 30 days Methadone Tablet 5mg, 10mg: 360 tablets per 30 days 40mg: 90 tablets per 30 days MORPHINE SULFATE Morphine Sulfate Liquid 10mg/5ml, 20mg/5ml: 960 ml per 30 days 100mg/5ml: 480 ml per 30 days Morphine Sulfate Oral Concentrate 480 ml per 30 days Morphine Sulfate Suppository 5mg, 10mg, 20mg: 120 Suppositories per 30 days 30mg: 84 Suppositories per 30 days Morphine Sulfate IR Tablet 15mg: 30mg: 90 tablets per 30 days OPIUM Opium Tincture 960 ml per 30 days Page 3 of 10

SHORT-ACTING OPIOIDS OPIUM-BELLADONNA Opium-Belladonna Suppository 120 Suppositories per 30 days OXYCODONE Oxycodone HCL Liquid 5mg/5ml: 960 ml per 30 days 100mg/5ml: 480 ml per 30 days Oxycodone HCL Oral Concentrate 480 ml per 30 days Oxycodone HCL IR Capsule 180 capsules per 30 days Oxycodone HCL IR (Oxecta, Roxicodone) Tablet 5mg, 7.5mg, 10mg: 15mg, 20mg: 120 tablets per 30 days 30mg: 90 tablets per 30 days OXYCODONE-ACETAMINOPHEN Oxycodone-Acetaminophen (Roxicet) Liquid 960 ml per 30 days Oxycodone-Acetaminophen (Magnacet, Percocet, Primlev, 270 tablets per 30 days Xolox) Tablet 2.5-325mg, 5-300mg, 5-325mg 5-300mg, 5-400mg, 5-500mg, 7.5-300mg, 7.5-325mg, 7.5-400mg, 7.5-500mg, 10-300mg, 10-325mg, 10-400mg, 10-500mg, 10-650mg OXYCODONE-ASPIRIN Oxycodone-Aspirin (Percodan)Tablet OXYCODONE-IBUPROFEN Oxycodone-Ibuprofen Tablet Maximum daily dose 5 tablets OXYMORPHONE Oxymorphone (Numorphan) Suppository 120 suppositories per 30 days Oxymorphone HCL Tablet 5mg: 10mg: 90 tablets per 30 days COUGH COMBINATIONS Cotabflu 20-4-500 MG Tablet Allfen CD 10-400 MG Tablet Maxifed CD 10-400-60 MG Tablet Maxiflu CD 10-400-40-500 MG Tablet Maxiflu CDX 20-400-60-500 MG Tablet Phenflu CD 10-400-10-500 MG Tablet Phenflu CDX 20-400-10-500 MG Tablet Tussigon 5-1.5 MG Tablet Tussicaps ER 5-4 MG Capsule Tussicaps ER 10-8 MG Capsule Allfen CDX 20-200 MG/5mL Liquid Codeine-Promethazine 10-6.25 MG/5mL Hydrocodone-Chlorpheniramine ER Liquid Hydrocodone-Homatropine Liquid Hydromet 5-1.5 MG/5mL Liquid J-COF DHC 7.5-3-15 MG/5mL Liquid J -MAX DHC 7.5-100MG/5mL Liquid KG-Tussin 5-4-60 MG/5mL Liquid 180 capsules per 30 days 240 ml per 30 days Page 4 of 10

COUGH COMBINATIONS Promethazine VC with Codeine Liquid Rezira 5-60 MG/5mL Liquid Tussionex ER Suspension Vituz 5-4 MG/5mL Liquid Hycofenix 2.5-200-30 MG/5mL Liquid Obredon 2.5-200 MG/5mL Liquid Tuzistra XR 14.7-2.8 MG/5mL Liquid Zutripro 5-4-60 MG/5mL Liquid DETOXIFICATION AGENTS Naloxone (Evzio) injection Naloxone (Narcan) nasal spray Naltrexone tablet 0.8 ml (2 auto-injectors) per 30 days 2 units per 30 days HEADACHE COMBINATIONS Butalbital-caffeine-aspirin (Fiorinal) capsule Codeine-butalbital-caffeine-APAP tablet Codeine-butalbital-caffeine-APAP capsule Codeine-butalbital-caffeine-aspirin capsule PAIN CONTROL Maximum daily dose 6 capsules/tablets Buprenorphine (Butrans) patch Buprenorphine (Belbuca) buccal film Butorphanol nasal spray Pentazocine-acetaminophen tablet Pentazocine-naloxone tablet Tapentadol (Nucynta) tablet Tapentadol (Nucynta ER) extended-release tablet Tramadol (Ultram) tablet Tramadol ER (Conzip) capsule Tramadol ER (Ultram ER) tablet Tramadol HCL ER 150mg capsule Tramadol/Acetaminophen (Ultracet) tablet 4 patches per 28 days 60 films per 30 days 6 nasal units per 30 days 6 tablets per day 2 tablets per day 8 tablets per day 1 capsule per day 1 tablet per day 1 capsule per day 8 tablets per day PARENTERAL SHORT-ACTING OPIOIDS Note: Injectable opioid medications are specifically excluded under most benefit plans. Please refer to the applicable benefit plan document to determine benefit availability and the terms and conditions of coverage. Page 5 of 10

PARENTERAL SHORT-ACTING OPIOIDS When coverage is available for injectable opioid therapy, the quantity limitation is 1 ml per 30 days. General Background The Institute of Medicine (IOM) estimates that at least 1.5 million preventable adverse drug events occur within the healthcare system each year. The costs of these preventable adverse drug events have been estimated to exceed $4 billion annually. Certain preventable adverse drug events relate to improper medication use. The Food and Drug Administration (FDA) launched the Safe Use Initiative to avoid improper medication use. Improper medication use increases the risk of harm from medication, often resulting in hundreds of thousands of injuries or deaths each year. Many of these injuries and adverse events could have been prevented with currently available knowledge. s are placed on pharmaceutical products to assure appropriate dosing and safe medication use as published in the FDA Product Information or Label. Employers that have selected Cigna Health Care benefit plans may choose s as a part of the pharmacy benefit program. The rationale for each drug or therapy group of s is defined in the table below. Therapeutic Drug Category Long Acting Opioids Fentanyl (Duragesic) patch Hydrocodone (Zohydro ER) Hydromorphone (Exalgo) Morphine sulfate (Arymo ER, Avinza, Kadian, Morphabond ER, MS Contin) Morphine sulfate/naltrexone (Embeda) extended-release tablet Oxycodone (OxyContin) Rationale review of doses exceeding what was studied in clinical trials). review of doses exceeding what was studied in clinical trials). review of doses exceeding either the usual dosing schedule or a more frequent than recommended schedule [to allow for patient variability in dosing requirements]). review of doses exceeding either the usual dosing schedule or a more frequent than recommended schedule [to allow for patient variability in dosing requirements]). Page 6 of 10

Therapeutic Category Drug Oxycodone (Xtampza ER) Short Acting Opioids Codeine sulfate Acetaminophen/codeine (Tylenol with Codeine) Carisoprodol/aspirin/codeine (Soma Compound with Codeine) Dihydrocodeine/ acetaminophen/caffeine (Trezix) Dihydrocodeine/aspirin/ caffeine (Synalgos-DS) Fentanyl (Abstral, Actiq, Fentora, Lazanda, Onsolis, Subsys) transmucosal Hydrocodone/acetaminophen (Lortab, Norco, Vicodin, Vicodin ES, Vicodin HP, Xodol) Hydrocodone/ibuprofen (Reprexain, Vicoprofen, Xylon) Hydromorphone (Dilaudid) Levorphanol Methadone Rationale maximum recommended daily dose is 288 mg per day (eight 36 mg capsules, equivalent to 320 mg oxycodone HCl per day) maximum recommended daily dose is 360mg) maximum recommended daily dose is 360mg of codeine and 4000mg of acetaminophen for individuals 12 years and older. For individuals 3 to 12 years of age: Acetaminophen 75mg/kg per 24 hours, not to exceed 4000 maximum recommended daily dose is 8 tablets). maximum recommended daily dose is 10 capsules or tablets). maximum recommended daily dose for Abstral, Actiq, Lazanda, Onsolis, and Subsys is 4 doses; the FDA does not provide a maximum recommended dose for Fentora). maximum recommended daily dose of acetaminophen from all drug products should not exceed 4,000 maximum recommended daily dose is 5 tablets). Page 7 of 10

Therapeutic Category Drug Morphine sulfate Opium tincture Belladonna/opium suppository Oxycodone (Oxecta, Roxicodone) Oxycodone/acetaminophen (Magnacet, Percocet, Primlev, Roxicet, Xolox) Oxycodone/aspirin (Percodan) Oxymorphone (Numorphan) Cough Combinations Promethazine with codeine oral solution Hydrocodone/ pseudoephedrine (Rezira) oral solution Hydrocodone/ chlorpheniramine (Vituz) oral solution Hydrocodone/ pseudoephedrine/guaifenesin (Hycofenix) solution Hydrocodone/guaifenesin (Obredon) oral solution Hydrocodone/ chlorpheniramine (Tussionex) ER oral suspension Codeine/chlorpheniramine (Tuzistra XR) ER suspension Hydrocodone/ chlorpheniramine/ pseudoephedrine (Zutripro) oral solution Rationale maximum recommended daily dose is 4 doses). maximum recommended daily dose of acetaminophen from all drug products should not exceed 4,000 maximum recommended daily dose is 12 tablets). maximum recommended daily dose is 30 milliliters). maximum recommended daily dose is 20 milliliters). maximum recommended daily dose is 20 milliliters). maximum recommended daily dose is 40 milliliters). maximum recommended daily dose is 60 milliliters). maximum recommended daily dose is 10 milliliters). maximum recommended daily dose is 20 milliliters). maximum recommended daily dose is 20 milliliters). Page 8 of 10

Therapeutic Drug Category Detoxification Agents Naloxone (Evzio) injection Naloxone (Narcan) nasal spray Naltrexone tablet Headache Combinations Butalbital/acetaminophen/ caffeine/codeine (Fioricet with Codeine) capsule Butalbital/aspirin/caffeine (Fiorinal) capsule Pain Control Buprenorphine (Butrans) patch Buprenorphine (Bulbuca) buccal film Butorphanol nasal spray Pentazocine/acetaminophen tablet Pentazocine/naloxone tablet Tapentadol (Nucynta) tablet Tapentadol (Nucynta ER) extended-release tablet Tramadol (Ultram) tablet Tramadol (Conzip) extendedrelease capsule Rationale maximum recommended daily dose is 6 capsules). maximum recommended daily dose is 6 capsules). maximum recommended dose is (1) 20mcg/hour patch every 7 days). maximum recommended dose is 900 micrograms every 12 hours). maximum recommended daily dose is 6 tablets). maximum recommended daily dose is 12 tablets). maximum recommended daily dose is 600 maximum recommended daily dose is 500 maximum recommended daily dose is 400 Page 9 of 10

Therapeutic Category Drug Tramadol (Ultram ER) extended-release tablet Tramadol/ acetaminophen (Ultracet) tablet Rationale maximum recommended daily dose is 300 maximum recommended daily dose is 300 maximum recommended daily dose is 8 tablets). Coding/Billing Information Note: s is typically covered under pharmacy benefit plans. Certain prescription drugs require an authorization for coverage to ensure that appropriate treatment regimens are followed. Medical drug coding and diagnosis codes, however, are generally not required for pharmacy claims submissions, therefore, this section is not in use. References 1. McEvoy GK, ed. AHFS 2017 Drug Information. Bethesda, MD: American Society of Health-Systems Pharmacists, Inc; 2017. 2. Individual Drug Name Entries. Drug Facts and Comparisons. Facts & Comparisons eanswers [online]. 2012, 2014. Available from Wolters Kluwer Health, Inc. Accessed April, 2017. 3. National Research Council. Preventing Medication Errors: Quality Chasm Series. Washington, DC: The National Academies Press, 2007. 4. U.S. Department of Health and Human Services Food and Drug Administration (FDA). FDA Safe Use Initiative. Nov 4, 2009. Accessed 4/18/2017. Available at http://www.fda.gov/downloads/drugs/drugsafety/ucm188961.pdf 5. U.S. Food and Drug Administration. Drugs@FDA. U.S. Department of Health & Human Services: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/. Cigna Companies refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Cigna Behavioral Health, Inc., Cigna Health Management, Inc., QualCare, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. The Cigna name, logo, and other Cigna marks are owned by Cigna Intellectual Property, Inc. 2018 Cigna. Page 10 of 10